All storiesEmerging therapies

CAR T-cell therapy shows lasting improvements in stiff person syndrome, study finds

A recent study suggests that CAR T-cell therapy may lead to sustained improvements in mobility and disability for people with stiff person syndrome, with benefits lasting at least one year.

NeoMD Editors · 2026-10-22 · 02:45 AM EDT

For information, not personal medical advice. Discuss treatment decisions with a qualified clinician.

The quick read

Key takeaways

CAR T-cell therapy, an immunotherapy previously used in cancer treatment, has shown potential in improving movement and reducing disability in patients with stiff person syndrome (SPS).
Improvements from CAR T-cell therapy in SPS patients persisted for at least one year post-treatment, suggesting a lasting benefit.
Details on study design, patient numbers, and control measures are unavailable, so results should be interpreted cautiously and require further research to confirm safety and effectiveness.

Editorial illustration for CAR T-cell therapy shows lasting improvements in stiff person syndrome, study finds — AI-generated editorial illustration.

What is stiff person syndrome?

Stiff person syndrome (SPS) is a rare neurological disorder characterized by muscle stiffness and spasms that can severely limit movement and daily activities. It is considered an autoimmune condition, where the body's immune system attacks its own nervous system.

The new research on CAR T-cell therapy

Researchers led by the University of Colorado Anschutz have investigated whether CAR T-cell therapy—a type of immunotherapy previously used in cancers—could help treat SPS. CAR T-cell therapy involves modifying a patient’s own immune cells to better target and eliminate harmful immune components.

The study reported that patients treated with this therapy experienced significant improvements in their ability to move and a reduction in overall disability. These benefits persisted for at least one year after treatment, suggesting a lasting positive effect.

Supporting editorial illustration for CAR T-cell therapy shows lasting improvements in stiff person syndrome, study finds — AI-generated editorial illustration.

Evidence and limitations

At this time, the details about the study design, including how many patients were involved, whether there was a control group, and how outcomes were measured, are not available. It is unclear whether the improvements were directly caused by the CAR T-cell therapy or if other factors contributed.

This means that while the results are promising, they should be interpreted cautiously. More research is necessary to confirm the therapy’s safety and effectiveness for SPS, as well as to understand potential side effects.

What this means for patients

The findings offer hope for people with stiff person syndrome, a condition that currently has limited treatment options. However, CAR T-cell therapy remains an experimental approach for SPS and is not widely available outside of research settings. Patients interested in this therapy should follow updates from ongoing clinical trials and consult healthcare providers for current best practices.

Source: Medical Xpress